SALT LAKE CITY, Nov. 12, 2024 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in nutrition, was recently awarded Manufacturer of the Year for the third consecutive year by the Utah Manufacturers Association in the "mega-sized (500+ employees) companies" category. To learn more about USANA and its commitment to quality, please visit USANA.com.   "Our manufacturing capabilities are one of our biggest differentiators as a company," said Jim Brown, CEO and president of USANA. "Our ability to manufacture the majority of our products in-house while maintaining extremely

SALT LAKE CITY, Nov. 1, 2024 /PRNewswire/ -- This November, a multinational leader is encouraging people everywhere to celebrate National Gratitude Month and experience the profound impact gratitude has on health and happiness. From enhancing psychological well-being to boosting physical health, gratitude has a transformative effect that can change lives in deeply meaningful ways. "I invite everyone to celebrate National Gratitude Month, a time dedicated to recognizing the lasting influence gratitude can have on our lives," said Kevin Guest, Executive Chairman at USANA Health

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 28, 2024. Key Financial & Operating Results Third quarter net sales were $200 million versus $213 million during Q3 2023. Third quarter diluted EPS was $0.56 as compared with $0.59 during Q3 2023. Company updates fiscal year 2024 net sales and diluted EPS outlook to approximately $850 million and $2.45, respectively (previously $850 million to $880 million and $2.40 to $2.55). Q3 2024 Financial Performance Consolidated Results Net Sales $200 million -6% vs. Q3 2023     No meaningful YOY FX impact     -6% sequentially D

SALT LAKE CITY, Oct. 10, 2024 /PRNewswire/ -- USANA Health Sciences, Inc. is proud to announce that the Prescribers' Digital Reference® (PDR) has recently included 11 of USANA's products to their list of trusted drugs and supplements. This recognition adds further credibility to the world-renowned quality of USANA's products while placing supplemental facts directly in the hands of prescribers. Products listed in the PDR include; BiOmega, CoQuinone 30, Core Minerals, HealthPak, Hepasil DTX, MagneCal D, USANA Probiotic, Procosa, Proflavanol C100, Visionex, and Vita Antioxidant.

USANA Health Sciences, Inc. (NYSE:USNA) today announced that third quarter 2024 results will be released after the close of market on Tuesday, October 22, 2024. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, October 23, 2024 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufacture

SALT LAKE CITY, Oct. 1, 2024 /PRNewswire/ -- As vibrant melodies of Country Music Month fill the air this October, there is no better time to explore the symphony between our love for music and the pursuit of mental wellness. Country music, with its rich storytelling and emotional resonance, offers more than just a soundtrack to our lives—it serves as a guiding force in achieving mental well-being, according to Kevin Guest, Executive Chairman at USANA Health Sciences (NYSE:USNA). "Our commitment to health is underscored by the power of music to transform lives," said Guest, wh

40 Gold, 33 Silver, and 26 Bronze won SALT LAKE CITY, Sept. 19, 2024 /PRNewswire/ -- USANA Health Sciences, Inc. would like to congratulate all 265 sponsored USANA Athletes who competed at the 2024 Summer Olympic and Paralympic Games in Paris. In total, 99 medals were won by these athletes, including 40 Gold, 33 Silver, and 26 Bronze.  For more information about USANA and why it is one of the most trusted brands among Olympic and Paralympic athletes, click here. "I am beyond proud of all our USANA Athletes who won and competed at the Paris Olympics and Paralympics," said Brent

SALT LAKE CITY, Sept. 3, 2024 /PRNewswire/ -- Entrepreneurs play a critical role in driving innovation, economic growth, and stability, according to Kevin Guest, executive chairman at USANA Health Sciences, a global leader in health and wellness products. "Entrepreneurs are the lifeblood of today's economy," said Guest. "Their courage to take risks, ability to innovate, and unwavering determination are what drive progress and create opportunities across industries." In his bestseller, All the Right Reasons: 12 Timeless Principles for Living a Life in Harmony, Guest shares qual

SALT LAKE CITY, Aug. 19, 2024 /PRNewswire/ -- USANA Health Sciences, Inc. has recently added two new products to its line of high-quality, science-based products. Celavive Resurfacing Serum blends powerful, clinically proven ingredients formulated to visibly transform the look of your skin. Whey Protein Isolate is the ultimate protein supplement to fuel your body and support your personal health goals.* For more information about USANA and its Resurfacing Serum and Whey Protein Isolate, visit here. "I couldn't be more excited about the launch of these innovative new products,"

SALT LAKE CITY, Aug. 1, 2024 /PRNewswire/ -- Inspired by Olympians, Kevin Guest, executive chairman at USANA Health Sciences (NYSE:USNA), is urging all to dig deep into their inner strength to excel in their personal and professional life. "Today's elite athlete shows tremendous discipline, resilience, determination and grit, all traits that develop winners in life," Guest said. In his bestseller, All the Right Reasons: 12 Timeless Principles for Living a Life in Harmony, Guest shares qualities that bring harmony and success. "So much of life comes down to understanding your p

4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

SALT LAKE CITY, July 1, 2024 /PRNewswire/ -- Throughout July, Kevin Guest, executive chairman at USANA Health Sciences (NYSE:USNA), is emphasizing boosting social connections during "Social Wellness Month." Social wellness—the ability to form meaningful relationships and interact positively with others—not only enhances our emotional well-being but also significantly impacts our overall health. "Strong social connections reduce stress, improve mental health, and even extend life expectancy," said Guest. "In a world where digital interactions often replace face-to-face communic

SAN FRANCISCO, CA / ACCESSWIRE / December 12, 2023 / Helo Corp. (OTC:HLOC) ("Helo" or the "Company") is pleased to announce that Kevin Fuller has joined its executive team as president of Helo AI and chief marketing officer of Helo, effective December 1, 2023."We are delighted to welcome Kevin to our executive team," said Seán McVeigh, Helo's chief executive officer. "Kevin brings significant product development and marketing experience, arising from his previous roles as a senior executive with other leading technology and wellness companies. His passion and leadership add to the significant momentum of our Helo AI platform and upcoming products."Mr. Fuller, 53, served as cofounder and chie

USANA Health Sciences, Inc. (NYSE:USNA) today announced that consistent with the Company's planned succession strategy, Kevin Guest, USANA's Chief Executive Officer (CEO) since 2015 and Chairman of the Board since 2020, will transition to the role of Executive Chairman of the Company, effective July 1, 2023. At that time, Jim Brown, USANA's current President, will be named CEO of the Company. "It has been my great privilege to be part of USANA for over 30 years and to serve as CEO of this remarkable company for the last 8 years. I express my sincere appreciation for, and confidence in, USANA's extraordinary management team, employees and Associates for their relentless work in advancing US

USANA Health Sciences, Inc. (NYSE:USNA) today announced the appointment of Xia Ding to the company's board of directors effective October 11, 2021. Ms. Ding currently serves as Vice President of e-commerce Asia Pacific and Latin America at Nike and is well-regarded as an e-commerce and digital business leader. She has served in various management roles at several global online and omnichannel retailers, including Nike, JD.com and Hanesbrands. With the addition of Ms. Ding to the board as an independent director, the USANA board now has eight members, six of whom are independent. Kevin Guest, Chief Executive Officer and Chairman of the Board, commented, "I'm delighted to welcome Ms. Ding to

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 28, 2024. Key Financial & Operating Results Third quarter net sales were $200 million versus $213 million during Q3 2023. Third quarter diluted EPS was $0.56 as compared with $0.59 during Q3 2023. Company updates fiscal year 2024 net sales and diluted EPS outlook to approximately $850 million and $2.45, respectively (previously $850 million to $880 million and $2.40 to $2.55). Q3 2024 Financial Performance Consolidated Results Net Sales $200 million -6% vs. Q3 2023     No meaningful YOY FX impact     -6% sequentially D

USANA Health Sciences, Inc. (NYSE:USNA) today announced that third quarter 2024 results will be released after the close of market on Tuesday, October 22, 2024. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, October 23, 2024 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufacture

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal second quarter ended June 29, 2024. Key Financial & Operating Results Second quarter net sales were $213 million versus $238 million during Q2 2023. Second quarter diluted EPS was $0.54 as compared with $0.89 during Q2 2023. Company updates fiscal year 2024 net sales and diluted EPS outlook to $850 million to $880 million and $2.40 to $2.55 (previously $850 million to $920 million and $2.40 to $3.00). Q2 2024 Financial Performance Consolidated Results Net Sales $213 million -11% vs. Q2 2023     -8% constant currency vs. Q2 2023  

USANA Health Sciences, Inc. (NYSE:USNA) today announced that second quarter 2024 results will be released after the close of market on Tuesday, July 23, 2024. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, July 24, 2024 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended March 30, 2024. Key Financial & Operating Results First quarter net sales were $228 million versus $248 million during Q1 2023, and increased 2% sequentially in constant currency. First quarter diluted EPS was $0.86 as compared with $0.95 during Q1 2023. Company reiterates fiscal year 2024 net sales and diluted EPS outlook of $850 million to $920 million and $2.40 to $3.00. Q1 2024 Financial Performance Consolidated Results Net Sales $228 million -8% vs. Q1 2023     -5% constant currency vs. Q1 2023    

USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter 2024 results will be released after the close of market on Tuesday, April 30, 2024. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, May 1, 2024 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures hi

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended December 30, 2023. Key Financial Results & Guidance Fourth quarter net sales were $221 million versus $228 million during Q4 2022 and $213 million during Q3 2023. Fourth quarter diluted EPS was $0.87 as compared with $0.66 during Q4 2022. Fiscal year 2023 net sales were $921 million as compared with $999 million during fiscal year 2022. Fiscal year 2023 diluted EPS totaled $3.30 versus $3.59 during fiscal year 2022. Company provides initial fiscal year 2024 net sales and diluted EPS guidance of $850 million to $920 million and $2.40 to $3.00, respect

USANA Health Sciences, Inc. (NYSE:USNA) today announced that fourth quarter and fiscal year 2023 results will be released after the close of market on Tuesday, February 6, 2024. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, February 7, 2024 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA deve

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 30, 2023. Key Financial & Operating Results Third quarter net sales were $213 million versus $233 million during Q3 2022. Third quarter diluted EPS was $0.59 as compared with $0.78 during Q3 2022. Company narrows fiscal year 2023 net sales and diluted EPS outlook to $900 million to $920 million and $2.80 to $3.05, respectively (previously $900 million to $950 million and $2.65 to $3.30). Q3 2023 Financial Performance Consolidated Results Net Sales $213 million -9% vs. Q3 2022 -7% constant currency vs. Q3 2022 -$5 million YOY F

USANA Health Sciences, Inc. (NYSE:USNA) today announced that third quarter results will be released after the close of market on Tuesday, October 24, 2023. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, October 25, 2023 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures

DA Davidson analyst Linda Bolton Weiser maintains Usana Health Sciences (NYSE:USNA) with a Neutral and lowers the price target from $46 to $38.

Usana Health Sciences (NYSE:USNA) reported quarterly earnings of $0.54 per share which missed the analyst consensus estimate of $0.65 by 16.92 percent. The company reported quarterly sales of $212.869 million which missed the analyst consensus estimate of $221.032 million by 3.69 percent. This is a 10.64 percent decrease over sales of $238.202 million the same period last year.

Usana Health Sciences's (NYSE:USNA) short percent of float has risen 18.01% since its last report. The company recently reported that it has 276 thousand shares sold short, which is 2.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.29 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short

Taking a multivitamin once a day has long been considered a path to better health, but a new study refutes that widely held belief. A study published in JAMA Network Open on Wednesday revealed that after tracking nearly 400,000 healthy adults for over 20 years, researchers found no link between regular multivitamin use and a lower risk of death, according to the National Institutes of Health. The study was led by researchers at the National Institutes of Health's National Cancer Institute. Also Read: Healthcare Advocates United: A Push For Congress To Recognize CBD As Dietary Supplements “The analysis showed that people who took daily multivitamins did not have a lower risk of de

DA Davidson analyst Linda Bolton Weiser maintains Usana Health Sciences (NYSE:USNA) with a Neutral and lowers the price target from $48 to $46.

Usana Health Sciences (NYSE:USNA) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.69 by 24.64 percent. This is a 9.47 percent decrease over earnings of $0.95 per share from the same period last year. The company reported quarterly sales of $227.800 million which beat the analyst consensus estimate of $226.853 million by 0.42 percent. This is a 8.28 percent decrease over sales of $248.360 million the same period last year.